Altogen Labs MCF7 Xenograft Service Breast Cancer
Altogen Labs http://altogenlabs.com provides xenograft services http://altogenlabs.com/xenograft-mode.... The MCF7 epithelial cell line was derived from adenocarcinoma of the human breast of a 69-year-old Caucasian female patient in 1970. The MCF7 cell line has been extensively employed in breast cancer research.
The MCF7 cell line is used to create the CDX (Cell Line Derived Xenograft) MCF7 mouse model, a powerful tool for studying cell death, apoptosis and mitotic arrest by chemotherapies such as docetaxel. Preclinical studies of the MCF7 mouse xenograft model can be valuable in the evaluation of breast cancer treatment, which is essential for patients with advanced stage disease.
Xenografting is the transplantation of tissue from one species into another.
Xenografting has been established as benchmark studies in pre-clinical cancer research.
Typically, immunodeficient mice serve as hosts for a wide variety of human tumors, effectively serving as models for human subjects.
Xenografting is a complete and accurate study of tumor growth and the activity of drug administration.
-MCF7 Xenograft Model
Sample Cell Lines Available
-MCF7 Xenograft Model
Advantages of Xenografting
Develop new therapeutic agents quickly, efficiently and cost-effectively
Evaluate the efficacy and toxicity of potential therapeutic agents
Evaluate target compound activity using in vivo system (human cells)
Predict cytotoxicity of cancer drugs
-MCF7 Xenograft Model
Basic Xenograft Study
Xenograft studies can be designed to:
Identify lead compounds
Optimize dose schedules
Identify combination strategies
-MCF7 Xenograft Model
Routes of drug administration:
Intratumoral
Intramuscular
Oral gavage
Intravenous
Intratracheal
Subcutaneous
Intraperitoneal
Continuous infusion
Intranasal
Using cutting-edge micro-injection techniques
-MCF7 Xenograft Model
Following options are available for the MCF7 xenograft model:
MCF7 Tumor Growth Delay (TGD; latency)
MCF7 Tumor Growth Inhibition (TGI)
Dosing frequency and duration of dose administration
MCF7 tumor immunohistochemistry
Alternative cell engraftment sites (orthotopic transplantation, tail vein injection and left ventricular injection for metastasis studies, injection into the mammary fat pad, intraperitoneal injection)
Blood chemistry analysis
Toxicity and survival (optional: performing a broad health observation program)
Gross necropsies and histopathology
Positive control group employing cyclophosphamide, at a dosage of 50 mg/kg administered by intramuscular injection to the control group daily for the study duration
Lipid distribution and metabolic assays
Imaging studies: Fluorescence-based whole body imaging, MRI
-MCF7 Xenograft Model
Altogen Labs’ team of scientists carries extensive experience in Xenograft model research.
Altogen Labs is compliant as a Good Laboratory Practices (GLP) environment, which is required by the FDA for pre-clinical research.
Our Altogen Labs’ Xenograft services are extensive, rigorous, and flexible.
Contact us to discuss Xenograft model details, timeline estimates, and price quotes!
Connect to Altogen Labs:
LinkedIn - / altogen-labs
Twitter - https://twitter.com/altogen?lang=en
Facebook - / altogen.cro